Sodium-glucose co-transporter 2 inhibitors in peritoneal dialysis patients
Sodium-glucose co-transporter 2 inhibitors(SGLT2i),a novel type of oral antihyperglycaemic drugs,have demonstrated favorable cardiorenal protective effects in patients with type 2 diabetes or non-diabetic individuals.They can also improve cardiorenal outcomes in patients with chronic kidney disease.Although clinical trials have expanded the inclusion criteria for estimated glomerular filtration rate(eGFR)to lower levels,patients with eGFR＜20 ml/min/1.73m＾2 are still excluded.Whether the continuation of cardiorenal protective effects of SGLT2i during the maintenance dialysis phase is an area of clinical focus.Additionally,the anti-inflammatory and anti-fibrotic properties of SGLT2i may benefit the preservation of peritoneal function in patients undergoing peritoneal dialysis(PD).Therefore,further exploration of the application of SGLT2i in PD patients is warranted.
NETL
NSTL
万方数据
